Canaccord believes the Teva‘s (TEVA) legal filing is a result of not having gotten the traction they expected from their launch of generic mifepristone. Teva claims that Corcept’s (CORT) relationship with Optime, the specialty pharmacy distributor for Korlym, is a monopoly which Canaccord believes believes lacks basis. Canaccord believes the weakness in Corcept caused by the legal filing is a buying opportunity and the reiterated their Buy rating and $38 price target on Corcept Therapeutics shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Teva sues Corcept over alleged mifepristone market monopoly, Reuters says
- Corcept Therapeutics price target raised to $65 from $44 at Truist
- Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
- Biotech Alert: Searches spiking for these stocks today
- Corcept Therapeutics price target raised to $70.50 from $61 at Ladenburg